Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published Announced on 11 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Based on results for the interim consolidated accounting period and the outlook from the third quarter onward, the demand outlook and exchange rates were reviewed. Shipments of products such as cosmetics-related products in the Functional Chemicals business have remained strong, while some shipments, including clinical development products, in the Pharmaceuticals, Medical and Health business are expected to be pushed back to the next period. Edible oils and fats and food functional materials are expected to be affected by higher raw material and fuel prices, consumers' preference for saving, and a shift in demand toward lower-priced products. The assumed average exchange rates have changed from USD ¥150 and EUR ¥180 to USD ¥158 and EUR ¥182.
| Item | Details |
|---|---|
| Net Sales | 319,000 Millions of yen → 321,500 Millions of yen（+0.8%） |
| Operating profit | 50,000 Millions of yen → 50,500 Millions of yen（+1.0%） |
| Ordinary income | 51,000 Millions of yen → 51,800 Millions of yen（+1.6%） |
| Profit attributable to owners of the parent | 39,000 Millions of yen → 41,000 Millions of yen（+5.1%） |
| Net income per share | 169.6 Yen/sen → 183 Yen/sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | Announced on 11 May 2026 |
| Previous-period results | Fiscal year ended March 2026: net sales of ¥257,967 million, operating income of ¥47,411 million, ordinary income of ¥50,366 million, net income attributable to owners of the parent of ¥40,550 million, and earnings per share of ¥176.34 |
| Reason for the revision | Based on results for the interim consolidated accounting period and the outlook from the third quarter onward, the demand outlook and exchange rates were reviewed. Shipments of products such as cosmetics-related products in the Functional Chemicals business have remained strong, while some shipments, including clinical development products, in the Pharmaceuticals, Medical and Health business are expected to be pushed back to the next period. Edible oils and fats and food functional materials are expected to be affected by higher raw material and fuel prices, consumers' preference for saving, and a shift in demand toward lower-priced products. The assumed average exchange rates have changed from USD ¥150 and EUR ¥180 to USD ¥158 and EUR ¥182. |
| Dividend forecast revision | The interim dividend has been increased from ¥35 to ¥37 per share. The year-end dividend forecast has been increased from ¥35 to ¥37 per share, bringing the annual dividend forecast from ¥70 to ¥74 per share. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The revision reflects results for the interim consolidated accounting period, the outlook from the third quarter onward, revised demand prospects, and a review of exchange rates. While products such as cosmetics-related products in the Functional Chemicals business have performed well, the forecast incorporates some shipments in the Pharmaceuticals, Medical and Health business being pushed back to the next period, higher raw material and fuel prices, consumers' preference for saving, and a shift in demand toward lower-priced products. The dividend was increased after taking into comprehensive consideration the policy for returning profits to shareholders, business performance, and financial condition.